Shilpa Gulati
Ophthalmology · Springfield, MANPI 1417375577
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,610 of the $25,199 with a category attached, or 77.8%. 15 manufacturers reported payments, led by Genentech USA, Inc. at 43.6% of the total. Reporting peaked in 2024 at $9,928 and has fallen 93.2% since, to $676 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $283.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$11K
- Regeneron$9K
- Genentech, Inc.$2K
- Alcon$762
- Regeneron Healthcare Solutions, Inc.$539
- Eyepoint US, Inc.$432
- plus $1K from 9 others
Across 3 payments — averaging $132,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$397K
What the payments were for
- Consulting fees$19,61078%
- Travel & lodging$1,9128%
- Food & beverage$3,25313%
- Education$880%
- Other$3371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 28 | $10,979 |
| Regeneron | 8 | $9,484 |
| Genentech, Inc. | 1 | $1,650 |
| Alcon | 6 | $762 |
| Regeneron Healthcare Solutions, Inc. | 14 | $539 |
| Eyepoint US, Inc. | 6 | $432 |
| Novartis | 5 | $370 |
| Alimera Sciences, Inc. | 4 | $322 |
| AbbVie(2 entities) | 5 | $228 |
| Astellas Pharma US Inc | 6 | $162 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Coherus Oncology, Inc. | 2 | $56 |
| Neurotech Pharmaceuticals, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $32 |
| Biogen | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,199 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 121 | $6,089 |
| Ofloxacin | 68 | $1,205 |
| Ketorolac Tromethamine | 31 | $513 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $504 |
| Brimonidine Tartrate | 26 | $212 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Springfield
- David LallySpringfield$328K
- Tavish NandaSpringfield$26K
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.